CDC-RFA-CK21-2106: Global Fungal Disease Surveillance and Capacity
Closed
This grant is closed. A newer notice from the same program is forecast: Capacity Building for National Immunization Programs in the Eastern Mediterranean Region (CDC-RFA-JG-27-0070). Status: Expected deadline February 12, 2027. It is in our archive of Centers for Disease Control - NCEZID notices from 2021.
Centers for Disease Control - NCEZID offered grants of up to $300,000 (at least $25,000) to any type of organization. It expected to make about 10 awards worth $2.5 million in total. Applications closed on July 27, 2021.
From the official notice on Grants.gov, last changed July 6, 2021. Checked November 7, 2026.
- Award ceiling$300,000
- Award floor$25,000
- Total funding$2.5 million
- Expected awards10
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | May 27, 2021 |
|---|---|
| Deadline | July 27, 2021 |
| Archived by Grants.gov | August 26, 2021 |
Who can apply
This opportunity was open to any type of organization.
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Consideration will be given to teaching hospitals associated with academic institutions, other global governmental entitites, and other organizations that demonstrate a history and capacity of global work, preferably experience conducting fungal activities globally. Individuals are not eligible for this opportunity.
Is this a realistic fit?
- Past Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security awards averaged $4.3 million; this notice allows up to $300,000 per award.
- Most of the program's money (49% over five years) went to nonprofits.
- No cost sharing or match is required.
What the grant funds
Fungal diseases pose a significant public health threat. Infections may be opportunistic, affecting those with weakened immune systems or living with HIV/AIDS, hospital or community acquired, and a growing number are multidrug-resistant. The outcome of this NOFO is to reduce illness and death due to fungal diseases and improve the clinical outcomes for patients with fungal disease. Some activities supporting this goal include monitoring trends in fungal disease burden, improving diagnostic capacity and treatment availability, and raising awareness among the public about the threat of fungal diseases. This NOFO addresses both known and emerging fungal pathogens. Strategies for this NOFO are four-fold: increase fungal surveillance by building epidemiology and laboratory capacity; support identification of known and emerging fungal pathogens for timely response; promote workforce development and provide training in the prevention and control of fungal diseases and increase awareness of fungal disease among the public; and monitor and evaluate the impact of these interventions and assess and refine performance metrics. These strategies are intended to promote health equity at the programmatic, infrastructural and policy levels. This NOFO recognizes that recipients may work to build the capacity to prevent and control specific fungal pathogens or may respond to emerging fungal pathogens or issues, such as antimicrobial resistance. As one of the only public health groups devoted to the prevention and control of fungal infections, MDB works with partners worldwide to understand who gets fungal infections, and why, by using epidemiologic, microbiologic, and bioinformatics approaches. MDB responds to emerging fungal threats, such as azole-resistant Aspergillus infections and COVID-19 associated aspergillosis. MDB partnered to identify and respond to an unknown pathogen in Pakistan in 2015, which turned out to be C. auris, a life-threatening, multidrug-resistant fungus that subsequently rapidly spread across the United States. MDB is responsive to emerging fungal needs across the globe. CDC’s Containment Strategy keeps new or rare forms of antibiotic resistance from spreading. Containment complements foundational CDC strategies, including improving antibiotic use and preventing infections, and builds on existing detection and response structure.
Who has won Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security grants before
From fiscal 2021 to 2025, Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security (93.318) awarded $1.3 billion across 306 grant awards, an average of $4.3 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| African Field Epidemiology Network LTD | 6 | $147 million | |
| The Task Force for Global Health, Inc. | Georgia | 7 | $138 million |
| World Health Organization, Somalia | 14 | $125 million | |
| Association of Public Health Laboratories, Inc. (the) | Maryland | 3 | $61.5 million |
| The Johns Hopkins University | Maryland | 5 | $42.7 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, CDC-RFA-JG-27-0070, which is forecast.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-CK21-2106 still open?
No. It closed on July 27, 2021. A newer notice is forecast: CDC-RFA-JG-27-0070, expected deadline February 12, 2027.
Who can apply for Global Fungal Disease Surveillance and Capacity?
Centers for Disease Control - NCEZID accepted applications from any type of organization. The notice adds further conditions, so read its eligibility section.
What is the deadline for Global Fungal Disease Surveillance and Capacity?
Closed July 27, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $300,000 each. About $2.5 million in total across about 10 awards.
Who has won Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security grants before?
The largest recipients over five fiscal years were African Field Epidemiology Network LTD, The Task Force for Global Health, Inc., World Health Organization, Somalia. The program made 306 awards worth $1.3 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)